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ABSTRACT
Background: Chronic viral hepatitis can be evaluated using invasive or noninvasive methods.
Objectives: The aim of this study was to evaluate liver stiffness in inactive HBsAg carriers com-
pared with normal subjects and determine if it is influenced by viral load in these patients.
Patients and Methods: We prospectively evaluated 140 inactive HBsAg carriers and 152 normal 
subjects (without any signs or history of liver disease). In all subjects, liver stiffness was meas-
ured by 3 experienced physicians using a FibroScan® device (EchoSens, France) per standard 
procedures. We excluded patients for whom the SR of liver stiffness measurements was < 60% 
and those who had measurements with an IQR >30%. 
Results: The mean liver stiffness in inactive HBsAg carriers was 5.6±2.1kPa, significantly higher 
than in normal subjects (4.8 ± 1.2 kPa, p = 0.0002). In 16.4% (23) of inactive carriers, liver stiff-
ness exceeded 7 kPa (the cutoff for significant fibrosis F ≥ 2). In patients with undetectable 
viral loads, the mean liver stiffness was 4.9 ± 1.2 kPa, significantly lower than in those with 
detectable DNA (< 2000 IU/ml) (6.7 ± 2.7 kPa, p < 0.001).
Conclusions: Inactive HBsAg carriers have higher liver stiffness values compared with healthy 
individuals. Liver stiffness in inactive HBsAg carriers with detectable viral loads is higher 
than in those who are aviremic, suggesting that low viral loads promote fibrosis.
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Background
Worldwide, chronic hepatitis B virus (HBV) infection is a sig-
nificant public health problem; approximately 350,000,000 
people are estimated to be infected with this virus. Some 
patients have chronic hepatitis or cirrhosis, whereas others 
are inactive carriers. Yet, it is possible that viral replication 
restarts in inactive HBsAg carriers, resulting in the develop-
ment of chronic hepatitis. In the past, nearly all patients with 
chronic HBV hepatitis were evaluated by liver biopsy (LB) to 
determine the stage and grade of the disease. Today, few pa-
tients undergo LB (those with less than a 2-fold increase in 
aminotransferase levels) to determine whether the liver le-
sions (especially necroinflammation) are severe enough to 
justify treatment.
Typically, inactive HBsAg carriers are not examined through 
invasive procedures, such as LB. Instead, liver lesion severity 
can be assessed noninvasively in inactive HBsAg carriers and 
chronic  HBV  hepatitis  patients  by  transient  elastography 
(TE)  or  biological  assay  (e.g.,  FibroTest-ActiTest).  In  recent 
years, new noninvasive methods of evaluation have become 
available, such as liver stiffness (LS) measurement by means 
of TE (FibroScan®) or biological tests (FibroTest-ActiTest®). 
These methods are tolerated easily by the patient and have 
good reproducibility (1). Further, they are not influenced by 
the subject's age (2) and, according to some studies, yield 
similar results as percutaneous LB (3, 4). After 2000, nonin-
vasive tests were used more frequently, particularly with the 
recognition of TE for the evaluation of patients with chronic 
HCV hepatitis (5). Recently, algorithms have been developed 
to assess chronic HBV hepatitis and nonalcoholic steatohep-
atitis.
There is a robust correlation between LS measurements (Fi-
broScan) and fibrosis, as diagnosed by LB, in HBV cirrhosis (4, 
  Implication for health policy/practice/research/medical education: 
Nowadays and thanks to non-invasive diagnostic methods of liver damages, there is an improvement in hepatology. This original article tries 
to open a new window for gastroenterologists, hepatologists, and other clinicians in the field.
  Please cite this paper as: 
Sporea I, Nicolita D, sirli R, Deleanu A, Tudora A, Bota S. Assessment of noninvasive liver stiffness in inactive HBsAg carriers by transient elas-
tography. Hep Mon. 2011;11(3):182-185.Hepat Mon. 2011;11(3):182-185
183 Sporea I  et al. Fibroscan in inactive HBsAg carriers
6-8). A meta-analysis of 7 studies demonstrated that TE has 
good predictive value for significant fibrosis (9), with 70% 
sensitivity (95% CI: 67% to 73%), 84% specificity (95% CI: 80% 
to 88%), a positive likelihood ratio of 4.2 (95% CI: 2.4-7.2), and 
a negative likelihood ratio of 0.31 (95% CI: 0.23-0.43). More-
over, the advantages of TE in evaluating inactive HBsAg car-
riers are that it detects the possible reactivation of disease 
and facilitates the diagnosis of other causes that can lead to 
liver injury (10, 11) for instance, concomitant alcohol abuse. 
Nevertheless, TE has disadvantages—the most significant of 
which is that liver stiffness (LS) can be influenced by factors 
other than liver fibrosis, such as ALT flares (12).
Objectives
The aims of this report were to evaluate LS in inactive HB-
sAg carriers compared with normal subjects and determine 
whether LS is influenced by viral load in these patients.
Patients and Methods
Patients
Our study group comprised 140 prospectivelly included, 
inactive HBsAg carriers. The diagnosis of inactive HBsAg car-
rier was based on the following criteria: persistent normal 
ALT and AST serum levels (at least 3 measurements during a 
6-month period), positive HBsAg, negative HBeAg, and HBV 
DNA viral load < 2000 IU/ml (< 10,000 copies/ml). The viral 
load  was  measured  by  real-time  PCR  (m2000sp/m2000rt 
Abbott), with a detection limit of 51 copies HBV DNA/ml (1.71 
log copies HBV DNA/ml). None of the patients was coinfected 
with HCV, HDV, or HIV. All patients were evaluated in the De-
partment of Gastroenterology and Hepatology, University of 
Medicine, Timişoara. The control group included 152 normal 
subjects—healthy volunteers or patients from other depart-
ments in our hospital (e.g., nephrology, surgery, cardiology). 
The healthy volunteers (109 individuals) were medical stu-
dents, nurses, and medical doctors (fellows and specialists) 
from our hospital. None had a history of liver disease (acute 
or chronic). At the TE evaluation, we did not perform addi-
tional tests in this subgroup, such as biological tests, viral 
markers, and abdominal ultrasonography.
The hospitalized patients (43 individuals) had no history 
of liver disease (acute or chronic), had normal aminotrans-
ferase levels, and did not exhibit stetatosis by ultrasonogra-
phy. Also, none had a severe disease, such as congestive heart 
failure, renal failure, and diabetes. Their chief diagnoses in-
cluded acute pyelonephritis, appendicitis, chronic glomeru-
lonephritis, arterial hypertension, and chronic angina pec-
toris. All subjects agreed to participate in this study, which 
was approved by the local ethical committee.
Transient elastography
LS measurements (LSMs) were taken by 3 experienced phy-
sicians (each performing more than 800 TE evaluations) by 
TE in all patients using a FibroScan® device (EchoSens - Paris, 
France). The intraobserver reproducibility of TE in our cen-
ter has been high (13), yielding intraclass correlation coeffi-
cients (ICCs) of 0.985, 0.949, and 0.874 for the 3 examiners, 
respectively. Also, the interobserver reproducibility was ex-
cellent for the examiners, with an overall ICC of 0.982. The 
measurements  were  made  with  the  patients  lying  in  the 
dorsal decubitus position with the right arm in maximal 
abduction. The right lobe of the liver was aimed at through 
the intercostal spaces. The tip of the probe transducer was 
covered with coupling gel and placed on the skin, between 
the ribs at the level of the right lobe of the liver. The opera-
tor, assisted by time-motion ultrasonography and A-mode 
images that were provided by the system, located a portion 
of the liver that was free of large vascular structures and at 
least 6 cm thick. Once the measurement area was identified, 
the operator pressed the probe button to begin an acquisi-
tion. Ten successful acquisitions were performed for each 
patient, and the median value was calculated by the device, 
expressed in kiloPascals (kPa) (14). The success rate (SR) was 
calculated as the ratio of the number of successful acquisi-
tions to the total number of acquisitions. Only patients in 
which 10 LSMs were obtained with an SR of at least 60% and 
with an IQR < 30% (IQR = interquartile range—the difference 
between the 75th and 25th percentiles, essentially the range 
of the middle 50% of the data) were considered to be reliable 
(15). Failure was defined as a case in which 10 valid measure-
ments could not be obtained. Failures and those with unre-
liable LSMs were not included in the analysis. LSM failures 
were  caused  primarily  by  abdominal  obesity  and  narrow 
intercostal spaces (15, 16).
Statistical analysis
The data were collected in a Microsoft Excel file. The sta-
tistical analysis was performed using Microsoft Excel and 
GraphPad  Prism.  The  mean  and  standard  deviation  were 
calculated for the quantitative variables. Unpaired t-test was 
used to compare means. Associations between assay results 
and viral load in inactive HBsAg carriers were analyzed using 
the Spearman rank correlation coefficient (r).
Results
The study group comprised 140 inactive HBsAg carriers, 
and the control group included 152 normal subjects; their 
demographic data are shown in Table 1. The mean LS value 
in the 140 inactive HBsAg carriers was 5.6 ± 2.1 kPa compared 
with 4.8 ± 1.2 kPa in the normal subjects (p = 0.0002), as seen 
in Figure 1. In 16.6% of cases (20 inactive HBsAg carriers), the 
LS  exceeded  7  kPa  (the  cutoff  for  significant  fibrosis),  re-
quiring further investigation to determine the cause. One 
HBsAg carrier had an LS of 20.1 kPa (indicating liver cirrho-
sis). Excluding this patient, the mean LS was 5.5 ± 1.7 kPa, sig-
nificantly higher than in normal subjects (4.8 ± 1.2 kPa) (p 
= 0.00017). The mean LS in patients with undetectable viral 
loads (86 patients) was 4.9 ± 1.2 kPa, lower than in patients 
with detectable DNA levels (under 2000 IU/ml- 54 patients) 
(6.7 ± 2.7 kPa, p < 0.001) (Figure 2). In determining whether 
viral load in HBsAg carriers correlated with LS, we observed 
that LS increased in patients with higher viral loads (under 
2000 IU/ml), but this result was not significant (Spearman         
r = 0.163, p = 0.365) (Figure 3).
Parameter Inactive HBsAg 
carriers (Mean ± SD)
Normal subjects 
(Mean ± SD)
p-value
Age (years) 38.7 ± 12.9 43.5 ± 15.9 0.0055
Male 69/140 (49.3%) 65/152 (42.8%) 0.2909
Body mass 
index (kg/m2)
25.15 ± 14.27 24.34 ± 4.7 0.8586
Table 1. Demographics of HBsAg carriers and normal subjects Hepat Mon. 2011;11(3):182-185
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Discussion
In  this  study,  we  determined  whether  TE  was  useful  for 
noninvasive  evaluation  of  liver  fibrosis  in  inactive  HBsAg 
carriers.  Hilleret  et  al.  (17)  examined  117  consecutive  inac-
tive HBsAg carriers during a 4-year period (2003-2007). They 
defined  inactive  HBsAg  carrier  status  as  follows:  HBsAg+; 
HBeAg-; anti-HBe +; normal ALT at least on 3 occasions during 
a minimal 6-month follow-up; HBV DNA lower than 4000 IU/
ml; anti-HCV, and anti-delta-negative. These inactive carriers 
were compared with 174 patients with histologically proven 
HBeAg- chronic hepatitis, evaluated in the same period. In 
each patient, LS was measured by FibroScan®. In inactive 
carriers, the mean LS was 4.9 kPa versus 8.6 kPa in patients 
with histologically documented HBeAg- chronic hepatitis (p 
< 0.001). Further, the mean LS in inactive carriers (excluding 
inactive cirrhosis) was compared with that of patients with 
mild HBeAg- chronic hepatitis (F0/F1 Metavir, N = 87). LS was 
significantly lower in inactive HBsAg carriers (4.9 vs. 8.1 kPa, 
respectively; p < 0.03). Also, in 95.6% of inactive carriers, LS 
was lower than 7 kPa, confirming the absence of significant 
fibrosis. 
In our study, the mean LS in inactive carriers was 5.7 kPa, 
compared with 4.9 kPa in the Hilleret study. Several studies 
have been published regarding the upper limit of normal 
LS values. In Chu et al. values under a cutoff of 6 kPa were 
highly predictive of insignificant fibrosis in patients with 
normal ALT levels (18). The cutoff was higher, 7.5 kPa, when 
ALT was elevated (up to 5 times the upper limit of normal 
[ULN]). In Roulot et al. (16), the proposed LS values for normal 
livers were 3.3–7.8 kPa in women and 3.8–8.0 kPa in men; in 
Corpechot et al. (19), the LS values ranged from 2.5–6.9 kPa. 
In a study by our group, the mean LS in 144 normal subjects 
was 4.8 ± 1.3 kPa (2).  Yet, Chan et al. (6), Oliveri et al. (10), and 
Coco et al. (12) demonstrated that LS values that are obtained 
by TE are influenced by transaminase levels and that this 
influence is absent in inactive carriers due to the persistent 
normal values of ALT in these subjects. Marcellin et al. (4) 
observed that TE adequately assesses LS in patients who are 
infected with HBV. In their study, which included 173 patients 
for whom both liver biopsy and TE were performed, LS cor-
related significantly with Metavir (r = 0.65) and Ishak fibro-
sis stage (r = 0.65) (p < 0.001). The areas under the receiver-
operating characteristic curves (AUROCs) were 0.81 (95% CI: 
0.73-0.86) for F ≥ 2, 0.93 (95% CI: 0.88-0.96) for F ≥ 3, and 0.93 
(95% CI: 0.82-0.98) for F = 4. The optimal LS cutoff values were 
7.2 and 11.0 kPa for F ≥ 2 and F = 4, respectively. The authors 
concluded that LS reliably detects significant fibrosis and 
cirrhosis in HBV patients and that the cutoffs differ slight-
ly from those in HCV patients. In inactive HBsAg carriers, 
one must determine whether their status is permanent or 
whether they require long-term follow-up. 
Viral  replication  can  restart  in  certain  inactive  carriers, 
causing chronic hepatitis (or cirrhosis) to develop. In Chu 
et al. (18), 1965 inactive HBsAg carriers were evaluated (mean 
age 35.6 years; 1076 males). During a mean follow-up of 11.5 
years, HBV hepatitis reactivated in 314 carriers (13%) (defined 
as  ALT  flares  more  than  twice  the  upper  limit  of  normal 
and positive HBV DNA by hybridization assay). The risk of 
HBV reactivation correlated significantly with older age on 
entrance into the study (p < 0.0001) and male gender (p < 
0.0001). Fifty-seven patients developed cirrhosis, for which 
the cumulative incidence was 15% after 25 years. The risk of 
cirrhosis correlated significantly with advanced age at entry 
(p = 0.004) and HBV reactivation (p < 0.0001). Of the 1651 car-
riers who did not experience HBV reactivation, 10 developed 
cirrhosis, and the only significant factor was advanced age 
at entry (p=0.03). Of the 314 patients with HBV reactivation, 
cirrhosis developed in 47, and the cumulative incidence was 
8%, 16%, 27%, and 46% at 5, 10, 15, and 20 years after reactiva-
tion. Male gender (p = 0.037) and advanced age at reactiva-
tion (p = 0.006) were independent risk factors. Chu et al. 
concluded that the so-called inactive carrier state cannot be 
considered generally as an innocuous, persistent condition 
with good prognosis, suggesting that regular follow-up is 
necessary. Based on these findings, we believe that regular 
follow-up of inactive HBsAg carriers by sequential viral load 
measurements (every 3–6 months) and annual LS measure-
ments constitute a reasonable workup for this category of 
patients.  In our study, one patient had a high LS values (20.1 
kPa)  and  no  biological,  endoscopic,  or  ultrasonographic 
Figure 1. Mean values of LS in normal subjects and HBsAg carriers
Figure 2. Mean LS values in patients with undetectable viral loads versus patients 
with detectable viral loads below 2000 IU/ml
Figure 3. Relationship between LS and viral load in inactive HBsAg carriers 
(Spearman r = 0.163, p = 0.365)
p = 0.0002
p < 0.001
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signs of cirrhosis. A liver biopsy was required to determine 
whether the patient had inactive cirrhosis, but he refused to 
undergo the procedure. We found that inactive HBsAg car-
riers had significantly higher LS values compared with nor-
mal subjects (5.6 ± 2.1 kPa vs. 4.8 ± 1.2 kPa, respectively; p = 
0.0002). Further, the mean LS in patients with undetectable 
DNA was 4.9 ± 1.2 kPa, lower than in patients with detectable 
DNA (but < 2000 IU/ml) (6.7 ± 2.7 kPa, p < 0.001), suggesting 
that low viral loads promote fibrosis. Although LS values in-
creased in patients with higher viral loads, the relationship 
was not significant (Spearman r = 0.163, p = 0.365). Inactive 
HBsAg carriers had higher LS values than normal subjects. 
The mean LS was lower in patients with undetectable viral 
loads than in patients with detectable viral loads, suggest-
ing that low viral loads accelerate fibrosis. Inactive HBsAg 
carriers with alarmingly high LS values (16.6% of patients 
had LS >7 kPa) require further examination, including liver 
biopsy. TE (FibroScan) is a good, noninvasive method that 
can be used to follow up these patients to assess the progres-
sion of fibrosis.
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